JPMorgan Chase & Co. Acquires Shares of 201,781 Ascendis Pharma A/S (ASND)

JPMorgan Chase & Co. acquired a new position in shares of Ascendis Pharma A/S (NASDAQ:ASND) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 201,781 shares of the biotechnology company’s stock, valued at approximately $7,163,000. JPMorgan Chase & Co. owned 0.55% of Ascendis Pharma A/S at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. RA Capital Management LLC boosted its position in Ascendis Pharma A/S by 3.2% during the second quarter. RA Capital Management LLC now owns 5,580,690 shares of the biotechnology company’s stock worth $154,920,000 after purchasing an additional 170,700 shares during the period. California Public Employees Retirement System bought a new stake in shares of Ascendis Pharma A/S in the second quarter valued at about $430,000. VHCP Management II LLC boosted its position in shares of Ascendis Pharma A/S by 21.6% in the second quarter. VHCP Management II LLC now owns 986,492 shares of the biotechnology company’s stock valued at $27,385,000 after acquiring an additional 175,000 shares during the period. Janus Henderson Group PLC bought a new stake in shares of Ascendis Pharma A/S in the second quarter valued at about $15,403,000. Finally, EcoR1 Capital LLC boosted its position in shares of Ascendis Pharma A/S by 44.5% in the second quarter. EcoR1 Capital LLC now owns 1,482,600 shares of the biotechnology company’s stock valued at $41,157,000 after acquiring an additional 456,900 shares during the period. 78.93% of the stock is owned by hedge funds and other institutional investors.

Shares of Ascendis Pharma A/S (ASND) opened at $40.09 on Thursday. Ascendis Pharma A/S has a 52-week low of $19.21 and a 52-week high of $42.00. The stock has a market cap of $1,460.00 and a PE ratio of -10.25.

A number of equities research analysts have recently issued reports on the stock. BidaskClub raised shares of Ascendis Pharma A/S from a “hold” rating to a “buy” rating in a research report on Wednesday. HC Wainwright reissued a “buy” rating on shares of Ascendis Pharma A/S in a research report on Wednesday, December 13th. Bank of America reduced their target price on shares of Ascendis Pharma A/S from $46.00 to $43.00 and set a “buy” rating for the company in a research report on Friday, November 17th. Wells Fargo & Co reissued a “buy” rating and issued a $51.00 target price on shares of Ascendis Pharma A/S in a research report on Friday, September 22nd. Finally, Credit Suisse Group reissued an “outperform” rating and issued a $50.00 target price (up previously from $30.00) on shares of Ascendis Pharma A/S in a research report on Friday, September 22nd. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating to the company. Ascendis Pharma A/S currently has an average rating of “Buy” and a consensus price target of $36.45.

TRADEMARK VIOLATION NOTICE: “JPMorgan Chase & Co. Acquires Shares of 201,781 Ascendis Pharma A/S (ASND)” was first posted by Community Financial News and is owned by of Community Financial News. If you are reading this report on another site, it was stolen and reposted in violation of US & international copyright law. The legal version of this report can be accessed at https://www.com-unik.info/2017/12/28/jpmorgan-chase-co-acquires-shares-of-201781-ascendis-pharma-as-asnd.html.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop sustained release prodrug therapies with several product candidates in clinical and preclinical development. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications.

Want to see what other hedge funds are holding ASND? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ascendis Pharma A/S (NASDAQ:ASND).

Institutional Ownership by Quarter for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit